Clinical trials
Progression clinical trials
Below are recruiting progression clinical trials, each written for real people, not researchers. We’re tracking 716 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT05837884Recruiting
Predicting who may develop myeloma in high-risk people
This study tries to predict which people at higher risk will develop myeloma (a blood cancer) and how quickly. It may help doctors spot problems earlier in people with family history and offer better follow-up.
BeershebaAges 30 years+ - NCT05780177Recruiting
Brief behavioral therapy for insomnia in PTSD veterans
This trial tests a short, structured behavioral program to help improve sleep problems (insomnia) in veterans who also have posttraumatic stress disorder (PTSD). It may help you fall asleep easier and sleep more consistently while continuing your usual care when it’s stable.
San Francisco, CaliforniaAges 18–75 - NCT05801471Recruiting
Tracking vision field changes in glaucoma patients
This study looks at different ways to measure how glaucoma affects your vision over time by comparing visual field results. It may help researchers find better models to track progression so treatment decisions can be made more accurately.
Milan, MilanoAges 40–90 - NCT05765812RecruitingPhase 1/Phase 2
Debio 0123 with temozolomide for recurrent or new glioblastoma
This early-phase study tests Debio 0123 (an anticancer medicine) combined with temozolomide, and for newly diagnosed patients also with radiation. It aims to see whether this treatment combination can slow or control glioblastoma in adults.
Chicago, IllinoisAges 18 years+ - NCT05758246RecruitingPhase 2
Fisetin to slow worsening of sepsis in older hospital patients
This Phase 2 trial tests whether a drug called fisetin can slow the progression of sepsis once you are admitted to the hospital. It may help patients recover more quickly or avoid worsening, but eligibility depends on how severe the illness is and what other treatments you need.
Gainesville, FloridaAges 65 years+ - NCT05773144Recruiting
Exercise program during chemotherapy for colon cancer recovery
This trial tests an aerobic exercise plan during chemotherapy for people with stage II or III colon cancer. It compares different exercise approaches to see if exercise can be done safely and may improve how you tolerate treatment and recovery.
Oakland, CaliforniaAges 18 years+ - NCT05533983Recruiting
Stool transplant plus nivolumab for advanced solid cancers
This study tests whether transferring stool microbiome (“FMT,” stool transplant) along with nivolumab can improve outcomes in people with advanced solid cancers that kept worsening even after anti–PD-1/PD-L1 treatment. It also looks at stool and blood changes to understand why the treatment might work.
SeoulAges 19 years+ - NCT05731427Recruiting
Study on what drives bronchiectasis worsening
This study looks at why bronchiectasis gets worse over time. It may help doctors understand the disease better and find better ways to monitor or treat it.
Guiyang, GuizhouAges 18 years+ - NCT04974671RecruitingPhase 2
SBRT radiation for limited cancer growth on immunotherapy
This trial tests whether targeted external-beam radiation (SBRT) can control a small number of progressing kidney cancer spots while you continue immune checkpoint inhibitor immunotherapy. It may help shrink or stop those specific “oligoprogressive” lesions and prolong benefit from your current immunotherapy.
New Haven, ConnecticutAges 18 years+ - NCT05700721RecruitingPhase 2
Niraparib and dostarlimab for cancer with growing brain spots
This trial studies whether the medicines niraparib and dostarlimab can slow advanced cancers that have active, growing brain metastases. It is meant for people whose brain tumors can be measured on MRI and who have had at least one previous treatment.
Houston, TexasAges 18 years+ - NCT05678166Recruiting
Testing a blood marker to predict worsening lung mycobacterial disease
This study checks whether a blood test called soluble programmed death-1 can help predict how nodular-bronchiectatic nontuberculous mycobacterial (NTM) lung disease will progress. Results may help doctors monitor patients more accurately and decide when to treat or follow more closely.
TaipeiAges 20 years+ - NCT05706220Enrolling by invitation
Eye tests to measure visual speed in multiple sclerosis
This study tests how fast and how accurately your eyes process visual information and how eye movements look in people with multiple sclerosis. It may help researchers understand vision-related effects of MS using objective eye measurements.
Valladolid, ValladolidAges 18–80 - NCT05686798RecruitingPhase 1
Gene therapy plus radiation for recurring brain tumor
This early-phase study tests a “suicide gene” therapy delivered by a virus along with radiation for adults whose high-grade brain tumor has come back or grown again. The goal is to see if the treatment is safe and can help control the tumor.
Detroit, MichiganAges 18 years+ - NCT05654922RecruitingPhase 3
Prevent lung transplant airways scarring with ARINA-1
This Phase 3 trial tests ARINA-1 to slow or prevent worsening lung transplant scarring in the breathing tubes (bronchiolitis obliterans). It may help people who are showing early decline in lung function but are not yet at advanced disease.
Phoenix, ArizonaAges 18–75 - NCT05659901Recruiting
Study tracks symptoms and test results in PLP1-confirmed PMD
This study follows children with Pelizaeus-Merzbacher disease (PMD) who have a specific genetic change (PLP1 duplication). It aims to learn which body measurements (“biomarkers”) and symptoms change over time, to better understand disease progression.
Atlanta, GeorgiaAges 6 months–17 years - NCT05646381RecruitingPhase 2
Drug study to slow hardening of aortic valve disease
This Phase 2 trial tests pelacarsen (TQJ230), a medication that lowers a blood fat called lipoprotein(a), to see if it slows progression of calcific aortic valve stenosis. It may help people whose valve narrowing is starting to become more severe, especially when their lipoprotein(a) level is high.
Huntsville, AlabamaAges 50–80 - NCT05641831RecruitingPhase 2
Canakinumab to prevent clonal blood count problems turning into cancer
This Phase 2 study tests canakinumab to help stop high-risk clonal cytopenias of unknown significance (CCUS) from progressing into a blood cancer. If you have persistent low blood counts and specific genetic features, this treatment may lower the chance of progression.
Miami, FloridaAges 18 years+ - NCT05612750Recruiting
Online therapy for chronic pain: CBT vs one-session relief
This study compares two online treatments for chronic pain: an 8-session cognitive behavioral therapy (CBT) program versus a single “empowered relief” session. It aims to see which approach helps people manage pain better over time.
Phoenix, ArizonaAges 18 years+ - NCT05565118RecruitingPhase 1
Brain activity study during surgery for high-grade glioma
This early-stage study measures electrical brain activity during brain tumor surgery to see if it can predict tumor return or progression. You may be offered the additional measurements while your surgeon removes a suspected or known high-grade glioma.
Cleveland, OhioAges 18 years+ - NCT05584397Enrolling by invitation
Compare immune activity and HIV hidden reservoir on two treatments
This study compares how active the immune system is and how large the “hidden” HIV reservoir is in people on two different HIV treatment types. It may help researchers understand whether staying on a tenofovir-containing regimen leads to better control of HIV hiding in the body.
Seattle, WashingtonAges 18–65 - NCT05585411Recruiting
Pacemaker type test to reduce heart worsening and death risk
This study compares two pacemaker pacing strategies—left-sided “bundle branch area” pacing versus right-sided ventricular pacing. It aims to see which approach better prevents heart failure getting worse and reduces abnormal timing between heart chambers over time.
Bucheon-siAges 19 years+ - NCT05588648RecruitingPhase 1/Phase 2
Vactosertib for recurrent or progressive bone cancer
This trial tests a new drug called vactosertib for people with a type of bone cancer called osteosarcoma that has come back or hasn't responded to other treatments. The goal is to see if the drug can help shrink or slow the cancer and to check its safety.
Cleveland, OhioAges 12 years+ - NCT03556228RecruitingPhase 1/Phase 2
Tested medicine for tumors with TrkA changes, alone or with pembrolizumab
This early-phase study tests VMD-928, a targeted cancer medicine, for cancers that have TrkA-related tumor changes. It may be given by itself or with pembrolizumab to see if it can shrink tumors when standard treatments have not worked.
Santa Rosa, CaliforniaAges 18–80 - NCT05528458RecruitingPhase 2
Osimertinib after surgery to stop leftover lung spots
This study tests whether osimertinib can prevent remaining abnormal lung spots (called ground-glass nodules) from growing after surgery. It is for people with lung cancer caused by specific EGFR gene changes (L858R or exon 19 deletion).
SeoulAges 30–75
Hear when a new Progression trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for progression?
- Yes. Clin2 currently lists 716 recruiting progression studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a progression trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a progression trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.